Partnering with Pharma:
The Dup15q Alliance was invited and attended an educational program put on by UCB (the makers of Briviact (brivaracetam), Vimpat (lacosamide), Keppra (levetiracetam))
that highlighted UCB’s science and commitment to epilepsy and it will be interactive and engaging. During this evening UCB gave a "tour" of their patient focused drug development initiative. The rare epilepsy voice was heard loud and clear throughout the evening from many of our partner epilepsy organizations and the call for better drugs that do not have such life altering side-effects was the cry.